Speaker of the House Mike Johnson says releasing the ethics committee report on the Florida lawmaker would set "a terrible ...

President-elect also nominates Tulsi Gabbard and Marco Rubio for senior roles, while Republicans are projected to win House ...

Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help prevent COVID-19. As with other drugs, Novavax can cause side effects, such as pain or swelling at the injection site ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year. The company now expects $650 million to $700 million in ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell ...

Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a ...

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...

Novavax expects 2024 revenues of $650 million-$700 million compared to prior guidance of $700 million-$800 million. The COVID-19 vaccine maker reported an EPS loss of $(0.76), up from $(1.26) a ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below ...